ASCO warns oncology nurses of the risks of ivermectin and fenbendazole, urging proactive patient communication and monitoring ...
The core of this optimization strategy is the geriatric assessment. At Mount Sinai, Jakubowski noted that patients aged 65 and older — and in some cases, those 60 and older — receive a comprehensive ...
Following the landmark results of the RASolute 302 trial, Mary Larsen, MSN, RN, OCN, a clinical trials nurse at Memorial ...
Hughes discusses managing GI toxicities and the need for research regarding GLP-1 use among breast cancer patients and survivors. As the clinical use of GLP-1 receptor agonists continues to rise, ...
CIBMTR data shows manageable toxicity and outpatient potential for liso-cel in R/R MCL, emphasizing the vital role of nursing ...
Diane Stanaway, MSN, RN, highlights the importance of long-term skin protection for oncology patients during high-exposure events like the World Cup. As the FIFA World Cup 2026 approaches, with the ...
FDA approves sacituzumab govitecan-hziy as monotherapy and with pembrolizumab for first-line treatment of advanced triple-negative breast cancer. On June 24, 2026, the Food and Drug Administration ...
The FDA approved palbociclib (Ibrance) for maintenance in HR+/HER2+ metastatic breast cancer after induction therapy, based on the PATINA trial. On June 24, the U.S. Food and Drug Administration (FDA) ...
Nicholas Hornstein, MD, PhD discusses ctDNA in colorectal cancer, the INTERCEPT-TT trial, building Northwell's GI oncology program, and what better drugs will look like. In this episode of The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results